EUVIMEDEUVIMED entdecken
Crossref

Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC

Melanie Hohberg, Manuel Reifegerst, Alexander Drzezga, Markus Wild, Matthias Schmidt

Journal of Nuclear Medicine · 2023-11 · 64 (11) · 1758-1764

DOI: 10.2967/jnumed.122.264953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 31.08.2023. Verfasst von Melanie Hohberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany melanie.hohberg@uk-koeln.de. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to analyze the absorbed dose of 177Lu-PSMA in osseous versus lymphatic metastases in patients with metastatic castration-resistant prostate cancer across therapy cycles and to relate those data to therapeutic success. In addition, pretherapeutic prostate-specific membrane antigen (PSMA) PET/CT was evaluated for its ability to predict response behavior.

Methods

The study comprised 30 patients with metastatic castration-resistant prostate cancer, each receiving at least 3 cycles of 177Lu-PSMA therapy. Prostate-specific antigen (PSA) values between baseline and 6 wk after the third therapy cycle were used to classify the patients as responders (PSA decline ≥ 50%) or nonresponders (unchanged or increasing PSA level). Quantitative SPECT/CT images were acquired 24, 48, and 168 h after application of 177Lu-PSMA. The absorbed dose for tumor lesions was calculated with dosimetry software. From the pretherapeutic PET/CT scan, the tumor-to-kidney uptake ratio was determined for different SUVs.

Results

Regardless of patient response, the kidneys received a mean dose of 0.55 ± 0.20 Gy/GBq per cycle. In the first therapy cycle, the lymph node lesions received a mean dose of 3.73 ± 1.65 Gy/GBq in responders and 1.86 ± 1.25 Gy/GBq in nonresponders (P < 0.01). For bone lesions, the respective mean doses were 3.47 ± 2.00 Gy/GBq and 1.48 ± 0.95 Gy/GBq (P < 0.01). When successive therapy cycles were compared, the mean dose was found to have been reduced from the first to the second cycle by 27% for lymph nodes and by 33% for bone lesions. A significant difference (P < 0.01) in the ratio of lymph node and bone lesion uptake to kidney uptake between responders and nonresponders could be deduced from the pretherapeutic PET/CT scan.

Conclusion

Significantly higher doses were achieved for lymph node and bone lesions in responders. The highest absorbed dose, for both lymphatic and osseous lesions, was achieved in the first cycle, decreasing in the second therapy cycle thereafter despite unchanged therapy activities. It may be possible to estimate the response to therapy from the ratio of tumor uptake to kidney uptake obtained from the pretherapeutic PSMA PET/CT scans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantMaleHumansProstate-Specific AntigenRadiopharmaceuticalsKidneyHeterocyclic Compounds, 1-RingLutetiumDipeptidesTreatment Outcome

Stichwörter der Autor:innen

PSMA therapydosimetryprediction of therapy responseprostate cancer

Substanzen

Prostate-Specific AntigenRadiopharmaceuticalsHeterocyclic Compounds, 1-RingLutetiumDipeptides

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany melanie.hohberg@uk-koeln.de.
  • Department of Nuclear Medicine and Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Zitieren

APA

Hohberg, M., Reifegerst, M., Drzezga, A., Wild, M., & Schmidt, M. (2023). Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. Journal of Nuclear Medicine, 64(11), 1758-1764. https://doi.org/10.2967/jnumed.122.264953

Vancouver

Hohberg M, Reifegerst M, Drzezga A, Wild M, Schmidt M. Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. Journal of Nuclear Medicine. 2023;64(11):1758-1764. doi:10.2967/jnumed.122.264953

BibTeX
@article{Hohberg2023,
  author = {Hohberg, Melanie and Reifegerst, Manuel and Drzezga, Alexander and Wild, Markus and Schmidt, Matthias},
  title = {Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {11},
  pages = {1758--1764},
  doi = {10.2967/jnumed.122.264953}
}
Kostenlos starten →